Persson E, Nordenström J, Nilsson-Ehle P, Hagenfeldt L
Eur J Clin Invest. 1985 Aug;15(4):215-20. doi: 10.1111/j.1365-2362.1985.tb00171.x.
Low molecular weight heparin (LMWH) and standard heparin were given intravenously to six healthy subjects receiving a continuous infusion of Intralipid. After infusion, antifactor Xa, antithrombin II and coagulation activity (Normotest) were the same for both heparins. Activated partial thromboplastin time increased significantly, but the increase was much higher after standard heparin (+473%) than after LMWH (+48%). The increase in lipoprotein lipase activity was less pronounced after LMWH infusion. This resulted in a smaller decrease in Intralipid-triglyceride concentration and a smaller increase in both plasma FFA concentration and Intralipid fractional removal rate compared to standard heparin. This study shows that the plasma lipolytic potential of LMWH is weaker than that of standard heparin when given in doses with equipotent anticoagulation. LMWH may therefore be preferable to standard heparin as an antithrombotic agent in clinical situations where a high plasma lipolytic activity may be disadvantageous.
将低分子量肝素（LMWH）和标准肝素静脉注射给6名接受脂肪乳持续输注的健康受试者。输注后，两种肝素的抗Xa因子、抗凝血酶II和凝血活性（正常凝血时间）相同。活化部分凝血活酶时间显著增加，但标准肝素后的增加幅度（+473%）远高于低分子量肝素后的增加幅度（+48%）。低分子量肝素输注后脂蛋白脂肪酶活性的增加不太明显。与标准肝素相比，这导致脂肪乳甘油三酯浓度下降较小，血浆游离脂肪酸浓度和脂肪乳分数清除率增加较小。这项研究表明，在给予等效抗凝剂量时，低分子量肝素的血浆脂解潜力比标准肝素弱。因此，在血浆脂解活性较高可能不利的临床情况下，低分子量肝素作为抗血栓药物可能比标准肝素更可取。
